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The capability of immunoactive muramyl peptides to bind specifically to rat brain membranes has been discovered. The 
reaction of an N-acetylglucosaminylmuramyl dipeptide analog having an additional C-terminal lysine residue (GMDP- 
Lys) with Bolton-Hunter reagent or N-hydroxysuccinimidyl-4-azidosalicylate afforded two acylated derivatives, GMDP- 
Lys-(Hp) and GMDP-Lys(Azs). Their iodination resulted in radioactive derivatives (spec. act. -2000 Ci/mmol) whose 
binding to rat brain membranes is characterized by Kd _ 3 nM and B,,, 5 10 fmol/mg membrane protein. Binding could 
be inhibited by muramyl dipeptide (MDP), GMDP-Lys, and GMDP, while fragments of the latter, N-acetylglucosamine, 
dipeptide and disaccharide, were ineffective. 
Muramyl peptide; Specific binding; (Rat brain) 
1. INTRODUCTION 
Muramyl peptides, the bacterial cell wall com- 
ponents, manifest a variety of biological activities 
that underlie the practical significance of both 
naturally occurring compounds and synthetic 
preparations [ 11. The immunostimulatory and 
pyrogenic properties of N-acetylmuramyl-L-ala- 
nyl-D-isoglutamine (muramyl dipeptide, MDP), a 
structural component of mycobacteria, are studied 
best in Freund’s complete adjuvant [2]. MDP and 
some analogs, including those with an N-acetyl- 
glucosamine moiety, prolong slow wave sleep and 
can be considered to be endogenous somnogenic 
factors [3]. Such activity implies the presence of a 
specific target in the brain, however, there are as 
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MDP was prepared as in [6], Bolton-Hunter reagent [7] was 
obtained from Fluka (Switzerland), Na’251 from lsotop 
(USSR), and chloramine T, BSA and Taps from Serva (FRG). 
The photoactivatable derivatives were irradiated on a 
Chromatoscop instrument at h,., 254 nm, samples being placed 
5-10 cm from the light source. Radioactivity was measured on 
a Compugamma (LKB) scintillation counter. Binding data were 
treated by the least-squares procedure using a program (in 
BASIC) developed for an Iskra-226 computer. Binding 
parameters were calculated as in [8]. 
2.1. GMDP-Lys(Hp) 
Abbreviations: Azs, 4-azidosalicyl; BSA, bovine serum The GMDP-Lys [9] solution (2 mg, 2.2 pmol) in 200 ~1 water 
albumin; GMDP, N-acetylglucosaminylmuramyl dipeptide; was mixed with Bolton-Hunter reagent (1.5 mg, 5.8pmol) in 
GMDP-Lys, GMDP-Lys(Azs) and GMDP-Lys(Hp), GMDP ISOr MeOH and then added to 200~1 of 0.05 M sodium 
analogs with free or acylated lysine side chain; Hp, borate buffer, pH 8.5. After incubation of the reaction mixture 
3-(4-hydroxyphenyl)propionyl; MDP, muramyl dipeptide; for 30 min at room temperature, the desired product was 
Taps, N-tris(hydroxymethyl)-3-aminopropanesulfonic acid isolated by HPLC (fig.la). 
yet no biochemical data available on the respective 
binding sites. 
Here, we report on the preparation of radioac- 
tive analogs of N-acetylglucosaminylQ3l-4)-N- 
acetyl-L-alanyl-D-isoglutamine, a compound 
previously studied in detail at our institute [4,5], 
and describe their detection with the aid of the 
specific binding sites for muramyl peptides in rat 
brain membranes. 
2. MATERIALS AND METHODS 
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2.2. GMDP-Lys(Aa) 
250 fig (906 nmol) N-hydroxysuccinimidyl-4-azidosalicylate 
[lo] in 25 ~1 dioxane was added to GMDP-Lys (8OOrg, 
900 nmol) in 200~1 sodium phosphate buffer (pH 7.5). The 
mixture was incubated at room temperature for 30 mitt and 
then separated by HPLC (fig.lb). 
2.3. GMDP-Lys([‘“I]Hp) 
A solution of GMDP-Lys(Hp) (45 fig, 40 nmol) in 15 ~1 of 
0.05 M sodium phosphate buffer (pH 7.5), 0.5 mCi Na12jI 
(2000 Ci/mmol) in 4~1 water, and 15Opg (535 nmol) 
chloramine T in 15 $1 of 0.05 M sodium phosphate buffer (pH 
7.5) were added to 15 pl of 0.25 M sodium phosphate buffer 
(pH 7.5). In 1 min Na&Of (200~8, 1 rmol) in 20~1 of the 
same buffer was added to the mixture that was subjected to 
HPLC 1 min later (fig.2a). 
GMDP-L~s([‘~~I]A.zs) was prepared and purified similarly to 
GMDP-L~s([‘~~I]H~). 
2.4. Membrane isolation 
Lysed membranes from rat brain were prepared essentially as 
in [ll]; the pellet obtained after the final centrifugation was 
resuspended in 25 mM Taps-KOH (pH 7.4) containing 1 mM 
MgS04, then frozen and stored at - 70°C. Protein concentra- 
tion in the membrane suspension was measured by the method 
of Petersen [12]. 
2.5. Binding assays 
Radioactive ligands were added in increasing amounts to 
250~1 membrane suspension (4 mg protein/ml) in buffer A 
[25 mM Taps-KOH (pH 7.4), 1 mM MgS04, 0.1% BSA]. In 
addition, a lOOOO-fold excess of GMDP-Lys was introduced in- 
to the control sample. After 2 h incubation at room 
temperature, the mixture was passed through GF/F filters 
(Whatman) preincubated for 12 h at 4°C in buffer A. Each 
filter was washed three times with the same buffer before assay- 
ing radioactivity. 
3. RESULTS AND DISCUSSION 
Treatment of GMDP-Lys with Bolton-Hunter 
reagent and subsequent separation of the reaction 
mixture (fig.la) result in a series of peaks eluting 
at higher MeOH concentrations vs the starting 
compound (eluting at lo-12% MeOH). Fractions 
A and A’ contain the Hp group (absorption max- 
imum 276 nm), each giving rise, on rechroma- 
tography, to a two-peak profile identical to the 
original A/A’ pattern. The latter is due to rapid 
interconversion of the anomers characteristic of 
GMDP and its derivatives 191. From these data we 
conclude that fractions A and A’ correspond to 
the modified glycopeptide, GMDP-Lys(Hp). 
After reacting GMDP-Lys with the active ester 
of 4-azidosalicylic acid, the similarly paired frac- 
tions B and B ’ (fig. lb) were obtained. Their ab- 
sorption maxima at 263 and 300 nm are 
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Fig.1. Separation of GMDP-Lys acylation products. (a) 
Modification with Bolton-Hunter reagent: Ultrasphere ODS 
column (0.46 x 25 cm), 0.1% ammonium trifluoroacetate 
buffer (pH 3.5), linear gradient of MeOH (lo-50%); (b) 
reaction with N-hydroxysuccinimidyl-4-azidosalicylate: 
Nucleosil 7C8 column (0.46 x 25 cm), 0.1% ammonium 
trifluoroacetate (pH 3.5), linear gradient of EtOH (lo-50%). 
Flow rate, 1 ml/min. Peaks A, A’, and B, B’, corresponding 
to GMDP-Lys(Hp) and GMDP-Lys(Azs), respectively, are 
indicated by the hatched areas. 
characteristic for azidosalicylic acid, and the inten- 
sity of these bands diminishes considerably upon 
UV irradiation. Therefore, fractions B/B’ repre- 
sent the photoactivable derivative, GMDP- 
Lys(Azs) . 
In ascertaining the optimal conditions for 
iodination and separation of the reaction products, 
we first synthesized GMDP-Lys(Hp) derivatives 
using unlabeled NaI. Two pairs of peaks M/M ’ 
and D/D’ eluted at higher MeOH concentration 
than peaks A/A’ of the starting compound 
(fig.2a). With higher NaI content in the reaction 
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Fig.2. Isolation of GMDP-Lys iodinated derivatives. (a) 
lodination of GMDP-Lys(Hp); Ultrasphere ODS column 
(0.46 x 25 cm), 0.1% ammonium trifluoroacetate buffer (pH 
3.5), MeOH gradient (lo-60%); (b) iodination of GMDP- 
Lys(Azs): Nucleosil 7C8 column (0.46 x 25 cm), 0.1% 
ammonium trifluoroacetate (pH 3.5), EtOH gradient 
(lo-60%). Flow rate, 1 ml/min. (-) Absorption at 225 nm; 
(0) radioactivity. 
mixture, the intensity of peaks D/D’ increases at 
the expense of peaks A and M. The change in pH 
from 2.0 to 9.0 induced bathochromic shifts of 
280-+310 and 282-315 nm in the absorption 
spectra of fractions M/M’ and D/D’, respective- 
ly. Such behavior is also characteristic of mono- 
and diiodotyrosine [13]. Therefore, peaks M/M ’ 
and D/D’ can be ascribed to the mono- and 
diiodinated derivatives of GMDP-Lys(Hp), respec- 
tively. 
In order to obtain a preparation of high specific 
radioactivity (-2000 Ci/mmol), it was necessary to 
use undiluted Na12?, thus leading to a con- 
siderable excess of GMDP-Lys(Hp) in the reaction 
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mixture. The radioactive product eluted similarly 
to peaks M/M’ and, consequently, was a 
monoiodinated derivative. 
Iodination of GMDP-Lys(Azs) resulted in two 
pairs of peaks (fig.2b) eluting later than peaks 
B/B’ of the initial compound. As judged from the 
absorption spectra, we attribute the UV-sensitive 
fractions E/E ’ and F/F ’ to the mono- and 
diiodinated derivatives of GMDP-Lys(Azs), 
respectively. The radioactive fractions obtained in 
the reaction with undiluted Na12? eluted at the 
position of peaks E/E’, hence corresponding to 
the monoiodinated derivative, GMDP- 
L~s([‘~~I]Azs). 
Both GMDP-L~s([‘~~I]H~) and GMDP- 
Ly~([i~~I]Azs) are capable of specific binding to rat 
brain membranes as illustrated for one of these in 
fig.3. The observed high level of nonspecific 
binding poses a serious problem. In several cases 
we could not reliably measure the specific binding, 
apparently due to some uncontrollable changes in 
the properties of membrane preparations. 
In view of these circumstances, our main conclu- 
sion on the specific interaction of muramyl pep- 
tides with rat brain was drawn after numerous 
repetitions of the experiments with various batches 
of radioactive ligands and different membrane 
preparations. 
The binding parameters determined from a Scat- 
chard plot were as follows: & 3.1 + 0.9 nM for 
GMDP-L~s([‘~~I]H~), 3.6 f 0.3 nM for MDP- 
Lys([ 1251]Azs); number of binding sites B,,, 11.1 + 
1.2 and 9.1 + 0.9 fmol/mg protein for the Hp and 
Azs derivatives, respectively. The Hill coefficients 
h of 1.14 and 1.07 characterize one class of 
homogeneous binding sites. 
Our results show that the binding parameters for 
GMDP derivatives are practically independent of 
the structure of the aromatic substituents at the 
lysine e-amino group. Interestingly, the introduc- 
tion of an iodoazidophenylalanine residue into 
MDP was found to increase the biological activity 
of the parent glycopeptide [14]. 
The interaction of GMDP derivatives with rat 
brain is characterized by the high affinity and ex- 
tremely low density of binding sites. The latter 
feature may be due to the isolation of membranes 
from whole brain homogenates, while the respec- 
tive binding centers are probably confined to a few 
brain structures. This idea is supported by elec- 
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Fig.3. Total (l), nonspecific (2) and specific (3) binding as a 
function of GMDP-L~s([‘~~I]H~) concentration (Q. Membrane 
concentration, 4 mg protein/ml; sample volume, 250 pl; 
incubation time, 2 h. (Inset) Scatchard plot. 
troencephalography data on the magnitude of 
responses evoked by MDP administration to dif- 
ferent substructures of rabbit brain [15]. 
Binding studies were carried out after 2 h in- 
cubation of radioactive ligands with membranes. 
Preliminary experiments howed this period to be 
optimal for achieving saturation. The observed 
slow binding correlates with the slow development 
of somnogenic activity upon MDP administration 
to brain [16]. 
To assess the role of structural factors in 
binding, we investigated the displacement of 
GMDP-L~s([‘~~I]H~) by its fragments (table 1). 
GMDP, GMDP-Lys, GMDP-Lys(Hp) and MDP 
inhibited binding with approximately the same 
potency. Practically no inhibition was observed 
with N-acetylglucosamine, disaccharide and dipep- 
tide fragments of GMDP, the value determined for 
the disaccharide being obviously within the limits 
of experimental error. Therefore, MDP is the 
minimal structural element required for the in- 
teraction with the brain. 
In addition to muramyl peptides, other en- 
dogenous factors display somnogenic activity: 6- 
sleep-inducing peptide (DSIP) (review [ 17]), 
Table 1 
Displacement of GMDP-L~s([‘~~I]H~) (5 x 10e9 M) with 
nonradioactive ligands 
Ligand Concentration Displacement 
(W5 M) (070) 
GMDP-Lys 6.9 28 i 5 
GMDP 8.2 29 f 5 
MDP 11.6 25 + 6 
N-Acetylglucosamine 25.9 <1 
N-Acetylglucosamine-ul+4)- 
N-acetylmuramic acid 
L-Ala-D-iGln 
Serotonin 
11.5 6*5 
26.4 <I 
14.1 <1 
prostaglandin D2 [16], and interleukin 1 [18]. 
Published data on receptors for these compounds 
in the central nervous system are sparse. Specific 
binding to brain .was demonstrated in the case of 
DSIP, but the dissociation constant Kd of 14pM 
[19] characterizes ites of relatively low affinity. 
The presence of specific binding sites for muramyl 
peptides on macrophages, their major targets, has 
been reported in [20,21]. Interestingly, the value 
& - 1 nM characterizing MDP-Lys interaction 
with macrophages [21] is close to the corre- 
sponding figure (-3 nM) for GMDP-Lys binding 
to rat brain membranes. Silverman and co-workers 
[21] observed competition between serotonin and 
MDP, and concluded that the interaction of 
muramyl peptides with macrophages is realized, at 
least in part, via serotonin receptors. The results 
obtained by MaSek WI also implicate 
serotoninergic systems in the biological activity of 
MDP. However, with rat brain membranes we 
observed no competition between serotonin and 
GMDP-Lys([“‘I]Hp). This is indicative of certain 
differences between the muramyl-peptide-binding 
sites on brain membranes and macrophages. 
Further studies with radioactive and photoac- 
tivatable analogs should help to provide a detailed 
characterization of the muramyl-peptide-binding 
sites in cells of the immune and central nervous 
systems. 
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